CY1110661T1 - Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως - Google Patents

Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως

Info

Publication number
CY1110661T1
CY1110661T1 CY20101100595T CY101100595T CY1110661T1 CY 1110661 T1 CY1110661 T1 CY 1110661T1 CY 20101100595 T CY20101100595 T CY 20101100595T CY 101100595 T CY101100595 T CY 101100595T CY 1110661 T1 CY1110661 T1 CY 1110661T1
Authority
CY
Cyprus
Prior art keywords
individual
polypalpteses
vascular
reduce
administering
Prior art date
Application number
CY20101100595T
Other languages
English (en)
Inventor
Roy Bicknell
Steven Suchting
Lorna Mary Dyet Stewart
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32328072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110661(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0227080A external-priority patent/GB0227080D0/en
Priority claimed from GB0321401A external-priority patent/GB0321401D0/en
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1110661T1 publication Critical patent/CY1110661T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Μέθοδος αναστολής της αγγειογενέσεως σε ένα άτομο το οποίο την έχει ανάγκη περιλαμβάνουσα τη χορήγηση ενός αντισώματος το οποίο συνδέεται επιλεκτικά με την εξωκυτταρική περιοχή του ανθρώπινου μαγικού μύλου (MR) στο άτομο. Αντίσωμα το οποίο έχει τις αλληλουχίες αμινοξέων i) έως iii), τις αλληλουχίες αμινοξέων iv) έως vi) ή τις αλληλουχίες αμινοξέων i) έως vi): i) S A S S S V S Υ Μ Y ii) L Τ S Ν L A S iii) Q Q W S S Ν Ρ L Τ iv) D Y N L N v)V I N P N Y G T T S Y N Q K F K G vi) G R D Y F G Y. Μέθοδος αναστολής της αγγειογενέσεως σε ένα άτομο το οποίο την έχει ανάγκη περιλαμβάνουσα τη χορήγηση του εξωκυτταρικού τομέα (κατάλοιπα 1-467) του MR ή ενός θραύσματος του το οποίο αναστέλλει την αγγειογένεση στο άτομο. Μέθοδος αναστολής της μεταναστεύσεως και/ή του πολλαπλασιασμού των ενδοθηλιακών κυττάρων περιλαμβάνουσα τη χορήγηση του εξωκυτταρικού τομέα του MR ή ενός θραύσματος του το οποίο αναστέλλει τη μετανάστευση και/ή τον πολλαπλασιασμό των ενδοθηλιακών κυττάρων.
CY20101100595T 2002-11-20 2010-06-29 Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως CY1110661T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227080A GB0227080D0 (en) 2002-11-20 2002-11-20 Antibodies and uses thereof
GB0321401A GB0321401D0 (en) 2003-09-12 2003-09-12 Antibodies,polypeptides and uses thereof
EP03778499A EP1565491B1 (en) 2002-11-20 2003-11-20 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Publications (1)

Publication Number Publication Date
CY1110661T1 true CY1110661T1 (el) 2015-06-10

Family

ID=32328072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100595T CY1110661T1 (el) 2002-11-20 2010-06-29 Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως

Country Status (15)

Country Link
US (4) US20060099143A1 (el)
EP (1) EP1565491B1 (el)
JP (2) JP4869603B2 (el)
AT (1) ATE462727T1 (el)
AU (1) AU2003285500B8 (el)
CA (1) CA2506724C (el)
CY (1) CY1110661T1 (el)
DE (1) DE60331945D1 (el)
DK (1) DK1565491T3 (el)
HK (1) HK1080869A1 (el)
IL (2) IL168646A (el)
MX (1) MXPA05005470A (el)
PT (1) PT1565491E (el)
SI (1) SI1565491T1 (el)
WO (1) WO2004046191A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480622T1 (de) * 2000-11-06 2010-09-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
US6926081B2 (en) * 2002-02-25 2005-08-09 Halliburton Energy Services, Inc. Methods of discovering and correcting subterranean formation integrity problems during drilling
EP2316853A3 (en) * 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabout (robo) mediated angiogenesis and uses thereof
JP4869603B2 (ja) * 2002-11-20 2012-02-08 キャンサー・リサーチ・テクノロジー・リミテッド 抗体、ポリペプチドおよびその使用
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
EP2104509A4 (en) * 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASCULAR PERMEABILITY
EP2468776A3 (en) 2007-02-09 2012-11-14 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
ES2567030T3 (es) 2009-09-03 2016-04-19 Cancer Research Technology Limited Inhibidores de CLEC14A
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
KR101223511B1 (ko) * 2009-10-23 2013-01-31 주식회사 알앤엘바이오 지방조직 유래 성체 줄기세포 이동을 유도하는 방법
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ, インコーポレイテッド 抗fgfr2抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
EP2841457B1 (en) * 2012-04-27 2019-04-24 Daiichi Sankyo Company, Limited Anti-robo4-antibody
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2022221314A1 (en) * 2021-04-16 2022-10-20 BioLegend, Inc. Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co A polypeptide produced in an endothelial cell line and DNA encoding it.
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999006423A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
JP2001514024A (ja) 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 50個のヒト分泌タンパク質
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
EP1068312A2 (en) 1998-04-09 2001-01-17 Genset 5' ests and encoded human proteins
CA2361840A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001012671A1 (en) * 1999-08-12 2001-02-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr16
AU1190801A (en) 1999-09-30 2001-04-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
ATE480622T1 (de) * 2000-11-06 2010-09-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
EP2316853A3 (en) * 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabout (robo) mediated angiogenesis and uses thereof
US20060160729A1 (en) 2002-06-27 2006-07-20 Li Dean Y Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
JP4869603B2 (ja) * 2002-11-20 2012-02-08 キャンサー・リサーチ・テクノロジー・リミテッド 抗体、ポリペプチドおよびその使用

Also Published As

Publication number Publication date
ATE462727T1 (de) 2010-04-15
DK1565491T3 (da) 2010-07-19
CA2506724A1 (en) 2004-06-03
WO2004046191A2 (en) 2004-06-03
US20060263369A1 (en) 2006-11-23
AU2003285500A1 (en) 2004-06-15
IL168646A (en) 2010-12-30
US8394381B2 (en) 2013-03-12
AU2003285500B2 (en) 2010-07-01
US20080166295A1 (en) 2008-07-10
JP5336566B2 (ja) 2013-11-06
WO2004046191A3 (en) 2004-07-29
EP1565491A2 (en) 2005-08-24
JP2006524485A (ja) 2006-11-02
JP4869603B2 (ja) 2012-02-08
AU2003285500B8 (en) 2011-02-03
EP1565491B1 (en) 2010-03-31
US20060099143A1 (en) 2006-05-11
US20080019963A1 (en) 2008-01-24
DE60331945D1 (de) 2010-05-12
IL204453A (en) 2014-02-27
JP2012050442A (ja) 2012-03-15
HK1080869A1 (en) 2006-05-04
PT1565491E (pt) 2010-07-06
SI1565491T1 (sl) 2010-08-31
MXPA05005470A (es) 2005-09-08
CA2506724C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
CY1110661T1 (el) Αντισωματα συνδεομενα με τον ανθρωπινο μαγικο μυλο (mr), πολυπεπτιδια και χρησεις τους για την αναστολη της αγγειογενεσεως
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DK1266025T3 (da) Protein-scaffolds for antistof-mimetika og andre bindingsproteiner
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
SE9901379D0 (sv) Receptor structures
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
NO20026286D0 (no) Nye peptider
DK1397380T3 (da) Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
DE69115917D1 (de) Humane gammainterferonantagonisten
DE69229269T2 (de) Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
JP2004511492A5 (el)
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
FI943146A0 (fi) Signaalipeptideistä vapaiden stafylokinaasien ilmentyminen
ATE414279T1 (de) Test für zelluläre immunität mittels an einen festen träger gebundener peptide
WO2004033705A3 (en) Viral interferon antagonists and uses therefor